Patent: 10,041,934
Summary for Patent: 10,041,934
| Title: | Whole cell assays and methods |
| Abstract: | The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free. |
| Inventor(s): | Laing; Lance Gavin (Orono, MN), Sullivan; Brian Francis (Medina, MN) |
| Assignee: | Celcuity LLC (Minneapolis, MN) |
| Application Number: | 15/192,280 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,041,934
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | September 25, 1998 | ⤷ Start Trial | 2036-06-24 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | February 10, 2017 | ⤷ Start Trial | 2036-06-24 |
| Imclone Llc A Wholly-owned Subsidiary Of Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | February 12, 2004 | ⤷ Start Trial | 2036-06-24 |
| Imclone Llc A Wholly-owned Subsidiary Of Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | March 28, 2007 | ⤷ Start Trial | 2036-06-24 |
| Amgen Inc. | VECTIBIX | panitumumab | Injection | 125147 | September 27, 2006 | ⤷ Start Trial | 2036-06-24 |
| Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | June 8, 2012 | ⤷ Start Trial | 2036-06-24 |
| Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | February 28, 2019 | ⤷ Start Trial | 2036-06-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
